PMID- 17914192
OWN - NLM
STAT- MEDLINE
DCOM- 20071109
LR  - 20211020
IS  - 1073-6085 (Print)
IS  - 1073-6085 (Linking)
VI  - 36
IP  - 2
DP  - 2007 Jun
TI  - Exploiting dendritic cells for active immunotherapy of cancer and chronic 
      infections.
PG  - 131-41
AB  - Dendritic cells (DCs) are important antigen-presenting cells (APCs) that can 
      prime naive T cells and control adaptive immune responses with respect to 
      magnitude, memory and self-tolerance. Understanding the biology of these cells is 
      central to the development of new generation immunotherapies for cancer and 
      chronic infections. This review presents a brief overview of DC biology and of 
      the preparation and use of DC-based vaccines.
FAU - O'Neill, David W
AU  - O'Neill DW
AD  - Pathology, New York University School of Medicine, Rusk Research Bldg., Room 718, 
      400 East 34th Street, NewYork, NY 10016, USA. david.o'neill@med.nyu.edu
FAU - Bhardwaj, Nina
AU  - Bhardwaj N
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Mol Biotechnol
JT  - Molecular biotechnology
JID - 9423533
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines)
SB  - IM
MH  - Antigen Presentation
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Chronic Disease
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy, Active/*methods
MH  - Infections/*therapy
MH  - Neoplasms/*therapy
MH  - Vaccines/immunology/*therapeutic use
RF  - 153
EDAT- 2007/10/05 09:00
MHDA- 2007/11/10 09:00
CRDT- 2007/10/05 09:00
PHST- 1999/11/30 00:00 [received]
PHST- 1999/11/30 00:00 [revised]
PHST- 1999/11/30 00:00 [accepted]
PHST- 2007/10/05 09:00 [pubmed]
PHST- 2007/11/10 09:00 [medline]
PHST- 2007/10/05 09:00 [entrez]
AID - MB:36:2:131 [pii]
AID - 10.1007/s12033-007-0020-6 [doi]
PST - ppublish
SO  - Mol Biotechnol. 2007 Jun;36(2):131-41. doi: 10.1007/s12033-007-0020-6.